SCHEMBL3830397

SCHEMBL3830397

CC1(C)C2CCC1(CS(=O)(=O)ON1C(=O)C3C(C1=O)C1C(=O)N(OS(=O)(=O)CC45CCC(CC4=O)C5(C)C)C(=O)C31)C(=O)C2

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
F2 P00734 2/20 0.52
PRSS1 P07477 2/20 0.52
PRSS2 P07478 2/20 0.52
PRSS3 P35030 2/20 0.52
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA5A P35218 2/20 0.46
CA5B Q9Y2D0 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823149 0.92 KMT2A (0.51) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL111905 0.91 KMT2A (0.55) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL4351752 0.90 KMT2A (0.49) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL382804 0.90 KMT2A (0.49) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL4356042 0.89 SMN1; SMN2 (0.48) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL16519683 0.88 ALDH1A1 (0.55) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL14564571 0.88 ALDH1A1 (0.55) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL135682 0.87 KMT2A (0.56) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL3076355 0.87 KMT2A (0.56) KMT2AALDH1A1MEN1SMN1; SMN2F2
SCHEMBL8907321 0.87 KMT2A (0.56) KMT2AALDH1A1MEN1SMN1; SMN2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038261-A1 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 2005-02-17 US claimed
EP-1449833-A1 BISIMIDE COMPOUND, ACID GENERATOR AND RESIST COMPOSITION EACH CONTAINING THE SAME, AND METHOD OF FORMING PATTERN FROM THE COMPOSITION Wako Pure Chemical Industries, Ltd. (JP) 2004-08-25 EP claimed
EP-1449833-B1 BISIMIDE COMPOUND, ACID GENERATOR AND RESIST COMPOSITION EACH CONTAINING THE SAME, AND METHOD OF FORMING PATTERN FROM THE COMPOSITION WAKO PURE CHEM IND LTD (JP) 2009-09-09 EP disclosed
US-7374857-B2 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 2008-05-20 US disclosed
US-20050038261-A1 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 2005-02-17 US disclosed
EP-1449833-A1 BISIMIDE COMPOUND, ACID GENERATOR AND RESIST COMPOSITION EACH CONTAINING THE SAME, AND METHOD OF FORMING PATTERN FROM THE COMPOSITION Wako Pure Chemical Industries, Ltd. (JP) 2004-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038261-A1 Bismide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition ASIC1, GAR1, RER1 KMT2A 1016/4885ALDH1A1 633/4885MEN1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.